{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:07:15Z","timestamp":1794017235847,"version":"4.8.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03435-w","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T11:43:39Z","timestamp":1755344619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Yichao","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"3435_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS. Pathogenesis of Triple-Negative breast cancer. Annu Rev Pathol. 2022;17:181\u2013204.","journal-title":"Annu Rev Pathol"},{"issue":"Suppl 7","key":"3435_CR2","doi-asserted-by":"publisher","first-page":"vii30","DOI":"10.1093\/annonc\/mdq279","volume":"21","author":"N Berrada","year":"2010","unstructured":"Berrada N, Delaloge S, Andr\u00e9 F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol. 2010;21(Suppl 7):vii30\u20135.","journal-title":"Ann Oncol"},{"key":"3435_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.clbc.2021.07.001","volume":"22","author":"SK Yadav","year":"2022","unstructured":"Yadav SK, Silwal S, Yadav S, Krishnamoorthy G, Chisti MM. A systematic comparison of overall survival between men and women with triple negative breast cancer. Clin Breast Cancer. 2022;22:161\u20139.","journal-title":"Clin Breast Cancer"},{"key":"3435_CR4","doi-asserted-by":"crossref","unstructured":"Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M et al. Triple negative breast cancer: updates on classification and treatment in 2021. Cancers (Basel). 2022;14:1253.","DOI":"10.3390\/cancers14051253"},{"key":"3435_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8:95.","journal-title":"NPJ Breast Cancer"},{"key":"3435_CR6","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329\u201334.","journal-title":"Clin Cancer Res"},{"key":"3435_CR7","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.drup.2020.100742","volume":"54","author":"L Mosca","year":"2021","unstructured":"Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54:100742.","journal-title":"Drug Resist Updat"},{"key":"3435_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.09.004","volume":"50","author":"F Schettini","year":"2016","unstructured":"Schettini F, Giuliano M, De Placido S, Arpino G. Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives. Cancer Treat Rev. 2016;50:129\u201341.","journal-title":"Cancer Treat Rev"},{"key":"3435_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andr\u00e9 F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275\u201381.","journal-title":"J Clin Oncol"},{"key":"3435_CR10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/j.2040-4603.2015.tb00641.x","volume":"5","author":"TC Tan","year":"2015","unstructured":"Tan TC, Neilan TG, Francis S, Plana JC, Scherrer-Crosbie M. Anthracycline-Induced cardiomyopathy in adults. Compr Physiol. 2015;5:1517\u201340.","journal-title":"Compr Physiol"},{"key":"3435_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","volume":"33","author":"AC Wolff","year":"2015","unstructured":"Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the National comprehensive cancer network experience. J Clin Oncol. 2015;33:340\u20138.","journal-title":"J Clin Oncol"},{"key":"3435_CR12","doi-asserted-by":"publisher","first-page":"300060520964340","DOI":"10.1177\/0300060520964340","volume":"48","author":"ZY Li","year":"2020","unstructured":"Li ZY, Zhang Z, Cao XZ, Feng Y, Ren SS. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. J Int Med Res. 2020;48:300060520964340.","journal-title":"J Int Med Res"},{"key":"3435_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(20)30747-6","volume":"22","author":"R Dent","year":"2021","unstructured":"Dent R, Rugo HS. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. Lancet Oncol. 2021;22:27\u20138.","journal-title":"Lancet Oncol"},{"key":"3435_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1078-0432.CCR-16-0162","volume":"23","author":"P Sharma","year":"2017","unstructured":"Sharma P, L\u00f3pez-Tarruella S, Garc\u00eda-Saenz JA, Ward C, Connor CS, G\u00f3mez HL, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in Triple-Negative breast cancer: combined analysis of two cohorts. Clin Cancer Res. 2017;23:649\u201357.","journal-title":"Clin Cancer Res"},{"key":"3435_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1078-0432.CCR-20-3646","volume":"27","author":"P Sharma","year":"2021","unstructured":"Sharma P, Kimler BF, O\u2019Dea A, Nye L, Wang YY, Yoder R, et al. Randomized phase II trial of Anthracycline-free and Anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III Triple-negative breast cancer (NeoSTOP). Clin Cancer Res. 2021;27:975\u201382.","journal-title":"Clin Cancer Res"},{"key":"3435_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ijc.33830","volume":"150","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y, et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial. Int J Cancer. 2022;150:654\u201362.","journal-title":"Int J Cancer"},{"key":"3435_CR17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djx258","volume":"110","author":"O Gluz","year":"2018","unstructured":"Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, et al. Comparison of neoadjuvant Nab-Paclitaxel\u2009+\u2009Carboplatin vs Nab-Paclitaxel\u2009+\u2009Gemcitabine in Triple-Negative breast cancer: randomized WSG-ADAPT-TN trial results. J Natl Cancer Inst. 2018;110:628\u201337.","journal-title":"J Natl Cancer Inst"},{"key":"3435_CR18","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1158\/1078-0432.CCR-22-0482","volume":"28","author":"O Gluz","year":"2022","unstructured":"Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, et al. De-escalated neoadjuvant chemotherapy in early Triple-Negative breast cancer (TNBC): impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial. Clin Cancer Res. 2022;28:4995\u20135003.","journal-title":"Clin Cancer Res"},{"key":"3435_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006\u201312.","journal-title":"J Clin Epidemiol"},{"key":"3435_CR20","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ. Cochrane Handbook for Systematic Reviews of Interventions 6.5 2024 [Available from: www.training.cochrane.org\/handbook"},{"key":"3435_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136.","journal-title":"ANZ J Surg"},{"key":"3435_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"3435_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"3435_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101\u201329.","journal-title":"Biometrics"},{"key":"3435_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"3435_CR26","first-page":"2411","volume":"12","author":"M Lv","year":"2011","unstructured":"Lv M, Li B, Li Y, Mao X, Yao F, Jin F. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prevention: APJCP. 2011;12:2411\u20137.","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"key":"3435_CR27","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/annonc\/mds603","volume":"24","author":"Y Fan","year":"2013","unstructured":"Fan Y, Xu B, Yuan P, Ma F, Wang J, Ding X, et al. Docetaxel\u2013cisplatin might be superior to docetaxel\u2013capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol. 2013;24:1219\u201325.","journal-title":"Ann Oncol"},{"key":"3435_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1179\/1973947815Y.0000000061","volume":"28","author":"P Kern","year":"2016","unstructured":"Kern P, Kalisch A, von Minckwitz G, P\u00fctter C, Kolberg HC, Pott D, et al. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival. J Chemother. 2016;28:210\u20137.","journal-title":"J Chemother"},{"key":"3435_CR29","doi-asserted-by":"publisher","first-page":"60647","DOI":"10.18632\/oncotarget.10607","volume":"7","author":"P Zhang","year":"2016","unstructured":"Zhang P, Yin Y, Mo H, Zhang B, Wang X, Li Q, et al. Better pathologic complete response and relapse-free survival after carboplatin plus Paclitaxel compared with epirubicin plus Paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget. 2016;7:60647\u201356.","journal-title":"Oncotarget"},{"key":"3435_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-016-3735-x","volume":"156","author":"T Zhu","year":"2016","unstructured":"Zhu T, Liu CL, Zhang YF, Liu YH, Xu FP, Zu J, et al. A phase II trial of dose-dense (biweekly) Paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer. Breast Cancer Res Treat. 2016;156:117\u201324.","journal-title":"Breast Cancer Res Treat"},{"key":"3435_CR31","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.2147\/OTT.S145934","volume":"10","author":"L Huang","year":"2017","unstructured":"Huang L, Liu Q, Chen S, Shao Z. Cisplatin versus carboplatin in combination with Paclitaxel as neoadjuvant regimen for triple negative breast cancer. Onco Targets Ther. 2017;10:5739\u201344.","journal-title":"Onco Targets Ther"},{"key":"3435_CR32","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.4149\/neo_2020_200130N96","volume":"67","author":"WP Li","year":"2020","unstructured":"Li WP, Zhu T, Hu MX, Yang M, Ji F, Gao HF, et al. Comparison of the efficacy and safety of the EC-T (epirubicin\/cyclophosphamide followed by docetaxel) and TCb (docetaxel\/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer. Neoplasma. 2020;67:1409\u201315.","journal-title":"Neoplasma"},{"key":"3435_CR33","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-18-0585","volume":"24","author":"P Sharma","year":"2018","unstructured":"Sharma P, L\u00f3pez-Tarruella S, Garc\u00eda-Saenz JA, Khan QJ, G\u00f3mez HL, Prat A, et al. Pathological response and survival in Triple-Negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res. 2018;24:5820\u20139.","journal-title":"Clin Cancer Res"},{"key":"3435_CR34","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1186\/s12885-018-4822-7","volume":"18","author":"RX Wang","year":"2018","unstructured":"Wang RX, Chen S, Huang L, Shao ZM. Predictive and prognostic value of matrix metalloproteinase (MMP) \u2013\u20099 in neoadjuvant chemotherapy for triple-negative breast cancer patients. BMC Cancer. 2018;18:909.","journal-title":"BMC Cancer"},{"key":"3435_CR35","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/annonc\/mdy201","volume":"29","author":"DA Yardley","year":"2018","unstructured":"Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the TnAcity trial. Ann Oncol. 2018;29:1763\u201370.","journal-title":"Ann Oncol"},{"key":"3435_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.21147\/j.issn.1000-9604.2020.04.06","volume":"32","author":"Q Li","year":"2020","unstructured":"Li Q, Wang J, Mu Y, Zhang T, Han Y, Wang J, et al. Dose-dense Paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with Paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chin J Cancer Res. 2020;32:485\u201396.","journal-title":"Chin J Cancer Res"},{"key":"3435_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10549-020-05660-z","volume":"181","author":"RX Wang","year":"2020","unstructured":"Wang RX, Ji P, Gong Y, Shao ZM, Chen S. Value of CXCL8-CXCR1\/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study. Breast Cancer Res Treat. 2020;181:561\u201370.","journal-title":"Breast Cancer Res Treat"},{"key":"3435_CR38","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","volume":"6","author":"KD Yu","year":"2020","unstructured":"Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant Paclitaxel and carboplatin on survival in women with Triple-Negative breast cancer: A phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1390\u20136.","journal-title":"JAMA Oncol"},{"key":"3435_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10549-021-06307-3","volume":"189","author":"FO Ademuyiwa","year":"2021","unstructured":"Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, et al. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat. 2021;189:187\u2013202.","journal-title":"Breast Cancer Res Treat"},{"key":"3435_CR40","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1002\/onco.13574","volume":"26","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Lee JS, Yost SE, Li SM, Frankel PH, Ruel C, et al. Phase II trial of neoadjuvant carboplatin and Nab-Paclitaxel in patients with Triple-Negative breast cancer. Oncologist. 2021;26:e382\u201393.","journal-title":"Oncologist"},{"key":"3435_CR41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41523-022-00500-3","volume":"8","author":"FO Ademuyiwa","year":"2022","unstructured":"Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, et al. A randomized phase 2 study of neoadjuvant carboplatin and Paclitaxel with or without Atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ Breast Cancer. 2022;8:134.","journal-title":"NPJ Breast Cancer"},{"key":"3435_CR42","doi-asserted-by":"publisher","first-page":"356","DOI":"10.53350\/pjmhs22168356","volume":"16","author":"RA Anwer","year":"2022","unstructured":"Anwer RA, Ghafor S, Ahmad H. Neoadjuvant docetaxel plus carboplatin versus epirubicin plus cyclophosphamide followed by docetaxel in Triple-Negative, Early-Stage breast cancer. Pakistan J Med Health Sci. 2022;16:356.","journal-title":"Pakistan J Med Health Sci"},{"key":"3435_CR43","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","volume":"33","author":"CE Geyer","year":"2022","unstructured":"Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O\u2019Shaughnessy J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from brightness, a randomized phase III trial. Ann Oncol. 2022;33:384\u201394.","journal-title":"Ann Oncol"},{"key":"3435_CR44","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1038\/s41467-022-31704-7","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang B, Sun T, Zhao Y, Wang S, Zhang J, Wang Z, et al. A randomized phase 3 trial of gemcitabine or Nab-paclitaxel combined with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nat Commun. 2022;13:4025.","journal-title":"Nat Commun"},{"key":"3435_CR45","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ijc.34022","volume":"151","author":"M Xiu","year":"2022","unstructured":"Xiu M, Zhang P, Wang X, Fan Y, Li Q, Li Q, et al. Survival outcomes for dose-dense Paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. Int J Cancer. 2022;151:578\u201389.","journal-title":"Int J Cancer"},{"key":"3435_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10549-021-06401-6","volume":"191","author":"F Zheng","year":"2022","unstructured":"Zheng F, Du F, Wang W, Wang Y, Li M, Zhao J, et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Res Treat. 2022;191:97\u2013105.","journal-title":"Breast Cancer Res Treat"},{"key":"3435_CR47","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/j.clbc.2022.12.008","volume":"23","author":"R Lobefaro","year":"2023","unstructured":"Lobefaro R, Mariani L, Peverelli G, Ligorio F, Fuc\u00e0 G, Rametta A, et al. Efficacy and safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in patients with advanced Triple-negative breast cancer: A monocentric, retrospective comparison. Clin Breast Cancer. 2023;23:e151\u201362.","journal-title":"Clin Breast Cancer"},{"key":"3435_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ijc.34717","volume":"154","author":"J Liu","year":"2024","unstructured":"Liu J, He M, Ou K, Wang X, Wang Y, Qi L, et al. Efficacy and safety of apatinib combined with dose-dense Paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. Int J Cancer. 2024;154:133\u201344.","journal-title":"Int J Cancer"},{"key":"3435_CR49","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1158\/1078-0432.CCR-24-0106","volume":"30","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Yoder R, Salgado R, Del Monte-Mill\u00e1n M, \u00c1lvarez EL, Echavarr\u00eda I, et al. Tumor-Infiltrating lymphocytes refine outcomes in Triple-Negative breast cancer treated with Anthracycline-Free neoadjuvant chemotherapy. Clin Cancer Res. 2024;30:2160\u20139.","journal-title":"Clin Cancer Res"},{"key":"3435_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12916-024-03474-0","volume":"22","author":"C Wang","year":"2024","unstructured":"Wang C, Yuan L, Wu X, Wang Y, Tian H, Zhang G, et al. Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study. BMC Med. 2024;22:252.","journal-title":"BMC Med"},{"key":"3435_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00432-024-05738-x","volume":"150","author":"H Wang","year":"2024","unstructured":"Wang H, Zhang N, Sun Q, Zhao Z, Pang H, Huang X, et al. Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis. J Cancer Res Clin Oncol. 2024;150:291.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3435_CR52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497\u2013509.","journal-title":"Lancet Oncol"},{"key":"3435_CR53","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747\u201356.","journal-title":"Lancet Oncol"},{"key":"3435_CR54","doi-asserted-by":"publisher","first-page":"770663","DOI":"10.3389\/fphar.2021.770663","volume":"12","author":"H Tian","year":"2021","unstructured":"Tian H, Ma D, Tan X, Yan W, Wu X, He C, et al. Platinum and taxane based adjuvant and neoadjuvant chemotherapy in early Triple-Negative breast cancer: A narrative review. Front Pharmacol. 2021;12:770663.","journal-title":"Front Pharmacol"},{"key":"3435_CR55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1185\/03007995.2012.756393","volume":"29","author":"WX Qi","year":"2013","unstructured":"Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin. 2013;29:117\u201325.","journal-title":"Curr Med Res Opin"},{"key":"3435_CR56","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.21037\/apm-22-690","volume":"11","author":"L Lei","year":"2022","unstructured":"Lei L, Chen R, Fan L, Zheng W, Wang X. Efficacy and safety of nanoparticle-albumin-bound Paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis. Ann Palliat Med. 2022;11:2382\u201394.","journal-title":"Ann Palliat Med"},{"key":"3435_CR57","doi-asserted-by":"publisher","first-page":"101096","DOI":"10.1016\/j.currproblcancer.2024.101096","volume":"50","author":"F Petrelli","year":"2024","unstructured":"Petrelli F, Ghidini A, Rea C, Parati MC, Borgonovo K, Ghidini M, et al. Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis. Curr Probl Cancer. 2024;50:101096.","journal-title":"Curr Probl Cancer"},{"key":"3435_CR58","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jcpt.13276","volume":"46","author":"W Wang","year":"2021","unstructured":"Wang W, Liu M, Ding B. Comparison of the short-term efficacy and serum markers between lobaplatin\/paclitaxel- and carboplatin\/paclitaxel-based adjuvant chemotherapy in patient with ovarian cancer. J Clin Pharm Ther. 2021;46:166\u201372.","journal-title":"J Clin Pharm Ther"},{"key":"3435_CR59","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/imj.12773","volume":"45","author":"JS Yang","year":"2015","unstructured":"Yang JS, Wang T, Qiu MQ, Li QL. Comparison of efficacy and toxicity profiles between paclitaxel\/lobapoatin- and cisplatin\/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. Intern Med J. 2015;45:757\u201361.","journal-title":"Intern Med J"},{"key":"3435_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","volume":"19","author":"JL Ethier","year":"2017","unstructured":"Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19:2.","journal-title":"Breast Cancer Res"},{"key":"3435_CR61","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1634\/theoncologist.2014-0290","volume":"20","author":"PG Sivasubramaniam","year":"2015","unstructured":"Sivasubramaniam PG, Zhang BL, Zhang Q, Smith JS, Zhang B, Tang ZH, et al. Breast cancer disparities: A multicenter comparison of tumor diagnosis, characteristics, and surgical treatment in China and the U.S. Oncologist. 2015;20:1044\u201350.","journal-title":"Oncologist"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03435-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03435-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03435-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:47:28Z","timestamp":1757393248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03435-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3435"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03435-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review and meta-analysis review, not human or animal experiments, so it does not require ethical approval from the ethics committee. As this study is a meta-analysis of previously published data, no new informed consent was required from individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This meta-analysis does not contain any individual person\u2019s data in identifiable form. Therefore, consent for publication is not applicable to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1567"}}